Traded @ BSE/NSE (506197)
Target : 200+
Bliss GVS is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. We are a public limited company listed on India?s National Stock Exchange and Bombay Stock Exchange with more than three decades of industry expertise.
We are among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Our thirty years of experience in suppositories manufacturing has resulted in developing an extensive product offering in suppositories and pessaries across various therapeutic categories (see here ). We follow European GMP Standards for manufacturing suppositories. Our manufacturing plants are certified to be cGMP compliant by local and international standards: EU GMP, WHO GMP, OHSAS-18001 : 2007 and ISO-14001 : 2004. We are the only EU-GMP certified suppositories manufacturer in India. We are constantly looking to raise the bar in terms of developing innovative products and quality standards which keep us ahead of competition in this dosage form.
Bliss GVS is proud of its segment leadership in Anti-malarial products across most African markets. Their, brands cover an extensive range of Artemisinin-based combination formulations across various dosage forms ? Tablets, Suspensions, Suppositories and Injections. Lonart is our flagship brand for Artemether & Lumefantrine combination, the fixed-dose recommended & pre-qualified by WHO for the treatment of uncomplicated malaria caused by plasmodium falciparum.
Over the last decade, They have expanded our portfolio to include a wider range of products across different therapeutic segments in order to cater to the increasing demands from countries in which we operate. In the dermatology segment, our Funbact brand is now prominent in the anti-fungal segment. To facilitate growth in this area, we have also added to our manufacturing capabilities in creams, ointments and gels. We are also rapidly building our manufacturing capabilities in herbal sore throat lozenges, a segment in which we have seen very high growth over the last few years. Thus, with significant expansion in R & D, Manufacturing & Marketing capabilities, we are poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS..
"Bliss GVS has enjoyed a phenomenal growth rate in excess of 30% CAGR over the last seven years.They, strongly believe this is a direct result of the organization being true to its principles. In response to growing customer demands, we have continuously enhanced our R&D and production capabilities and expanded our product portfolio across dosage forms and therapeutic segments. Today, I am proud to say that our portfolio comprises 250+ products that are consumed across 64 countries. Specifically, we are among the world-leaders in the Suppositories and Pessaries dosage form and our brands are recognized among the leading ones in the generic anti-malarial segment in most African countries. Over the years, we have thus successfully shaped sustainable business relationships across the globe that will provide the backbone for continued future growth.
One of the great privileges of working in the pharmaceutical industry is the opportunity to directly contribute towards the advancement of human quality of life. This has always been our greatest source of purpose in propelling Bliss GVS forward. Our goal of increased accessibility of quality medicines and healthcare across countries is very much central to this drive.
In order to achieve this goal, They, are committed to increasing our global reach whilst incorporating efficiency throughout our production and supply chain processes. Efforts are currently underway to adapt and expand our product distribution across Europe, South America, Asia-Pacific, Russia & CIS countries. We are scaling-up our capabilities across all functions including R&D to facilitate this expansion. We have also added additional product segments in herbals, small volume parentals, topicals and ointments through organic & inorganic routes.
These efforts and goals paint an ambitious and challenging roadmap ahead but one that all of us are excited to undertake. I am confident that given the dedicated team we have in place, Bliss GVS will maintain its upward trajectory to achieve new highs and continue to make an ever-increasing impact in improving patient life."
Celebration , Already Starts...........
You Just, Grab this Counter..........That's It..........!!!
We , Can't Write......Everything , Here...............
There's Little Hint..........A New Multi-Bagger is Making......
Oh Yes...
Buy @ 129 - 130
Today's Target : 148.50 - 153+Ultimate Target :200
SL : 110
No comments :
Post a Comment